Home›Research›Compare›AICAR vs Eloralintide
Peptide ComparisonAICAR vs Eloralintide
Both are Metabolic peptides.
Eloralintide
LY3841136
Half-life: Not published
1 providers listed
Eloralintide carries stronger published evidence (Meta-analysis, 4 key studies) than AICAR (Review, 6); both are research compounds.
AICAR
Eloralintide
| Your goal | Better option |
|---|---|
| Stronger clinical evidence | Eloralintide |
| Lower typical price per mg | AICAR |
| More provider options (5 vs 1) | AICAR |
Research summary only — not medical advice. Consult a qualified provider before making any decisions.
AICAR
Eloralintide
AICAR
MiR-27b-3p suppresses proliferation and testosterone synthesis in goat Leydig cells by activating the AMPK pa…
The AMPK-PGC-1α-SIRT3 axis mediates mitochondrial metabolic dysfunction and neuronal senescence induced by Al…
Berberine Regulates Hepatic Fatty Acid Metabolism via AMPK/SIRT1/PGC-1α Pathway.
Pharmacological inhibition of TRPM4 channel stabilizes atherosclerotic plaque via inhibiting AMPK-Beclin1-med…
+2 more
Eloralintide
Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A N…
Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of con…
Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentr…
Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to cli…
About AICAR
Converted intracellularly to ZMP, a potent AMPK activator. AMPK activation increases fatty acid oxidation, glucose uptake, and mitochondrial biogenesis — the same metabolic pathways activated by sustained aerobic exercise.
About Eloralintide
Selective long-acting amylin receptor agonist; preferentially activates AMY1R over the calcitonin receptor to prolong satiety and slow gastric emptying
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
AICAR
No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.
Eloralintide
Under clinical review
Being verified by our medical team before we display contraindications for this peptide.
No amylin-specific monitoring protocol is established for eloralintide, which remains investigational and is available only through clinical trials. Trial programmes track a baseline metabolic panel covering glycaemic markers, renal and hepatic function, and lipase. Calcitonin and TSH are carried over from incretin-class convention rather than from any eloralintide-specific signal, as the compound is designed for reduced calcitonin receptor activity.
AICAR
Eloralintide
Where to source these peptides
AICAR
5 listed
Browse directory →
Providers offeringEloralintide
1 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
More Metabolic Comparisons
Browse all peptides →Educational research tools — not medical advice.
Cite this page
Data last updated September 28, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). AICAR vs Eloralintide — Per-mg Price Comparison. Retrieved October 1, 2026, from https://peptidebase.io/peptides/compare/aicar/eloralintide